Key result
Early home rivaroxaban for low-risk PE yields a 0.6% recurrent VTE or PE-related death rate.
Why the study?
The study was conducted to investigate the efficacy and safety of early transition from hospital to ambulatory treatment using oral rivaroxaban in patients with low-risk acute pulmonary embolism.
Does early discharge and home treatment with rivaroxaban prevent recurrent VTE or PE-related death in patients with low-risk acute PE?
Does early discharge and home treatment with rivaroxaban prevent recurrent VTE or PE-related death in patients with low-risk acute PE?
Early discharge and home treatment with rivaroxaban is effective and safe in carefully selected patients with acute low-risk pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The main objective of the HoT-PE trial was to determine whether early discharge and out-of-hospital treatment with rivaroxaban with patients with acute low-risk PE — with an emphasis on selected patients — would be effective, safe and, indirectly, feasible.”
“We applaud Barco et al. for their multicentre single-arm management trial of 525 adults with acute low-risk pulmonary embolism who were directed to outpatient care on rivaroxaban after no more than two nights hospitalization. The low incidence of 3-month adverse events in the HoT-PE trial demonstrates the safety and effectiveness of their patient selection criteria and adds to the growing evidence supporting an early transition to ambulatory care either directly from the emergency department or after a short hospital stay.”
“The present analysis of the full cohort of 576 did not change the conclusions from those made on the basis of the previously published 525 patients, that an early discharge strategy is effective and safe for low-risk PE patients.”
Supports early home treatment with rivaroxaban in selected low-risk PE; leaves open need for randomized trials before practice change.
AIMS: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. METHODS AND RESULTS: We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was symptomatic recurrent venous thromboembolism (VTE) or PE-related death within 3 months of enrolment. An interim analysis was planned after the first 525 patients, with prespecified early termination of the study if the null hypothesis could be rejected at the level of α = 0.004 (<6 primary outcome events). From May 2014 through June 2018, consecutive patients were enrolled in seven countries. Of the 525 patients included in the interim analysis, three (0.6%; one-sided upper 99.6% confidence interval 2.1%) suffered symptomatic non-fatal VTE recurrence, a number sufficiently low to fulfil the condition for early termination of the trial. Major bleeding occurred in 6 (1.2%) of the 519 patients comprising the safety population. There were two cancer-related deaths (0.4%). CONCLUSION: Early discharge and home treatment with rivaroxaban is effective and safe in carefully selected patients with acute low-risk PE. The results of the present trial support the selection of appropriate patients for ambulatory treatment of PE.
No takes yet. Share an insight, caveat, or question.
Barco et al. (2019) studied acute low-risk pulmonary embolism (n=525). Rivaroxaban was evaluated on symptomatic recurrent venous thromboembolism (VTE) or PE-related death within 3 months of enrolment (95% CI upper 99.6% CI 2.1). Early discharge and home treatment with rivaroxaban in patients with acute low-risk pulmonary embolism resulted in a 0.6% rate of symptomatic recurrent VTE or PE-related death at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: